Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus SSRI for severe major depression with agitation
ChiCTR2000038915Phase 4Recruiting
- Sponsor
- The Third Hospital of Mianyang
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by The Third Hospital of Mianyang. Primary endpoints: HAMD-17, CADSS and 1 more. Started Nov 2020; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2000038915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038915.